Hofseth BioCare Private Placement
Analysis based on 10 articles · First reported Jun 29, 2026 · Last updated Jun 29, 2026
The successful private placement by Hofseth BioCare ASA, raising NOK 144.5 million, is likely to be viewed positively by the market as it strengthens the company's financial position. The increased stake of Hofseth International AS and Roger Hofseth's associated parties could signal strong insider confidence, while the dilution of other shareholders like CNH Industrial and Yokorei Co. Ltd. is a natural consequence of capital raising and may have a minor negative impact on their individual holdings.
Hofseth BioCare ASA completed a private placement on June 28, 2026, raising approximately NOK 144.5 million by issuing new ordinary shares at NOK 1.30 per share. Several primary insiders and their close associates, including Hofseth International AS, Christoph Baldegger, Crawford Currie, Joo Investments AS, Nevera AG, and Bomi Framroze Holding AS, were allocated shares. Hofseth International AS's holding in Hofseth BioCare ASA increased above the 20% threshold, while Scatterty Holdings Ltd. became a new significant shareholder. Conversely, existing shareholders like CNH Industrial and Yokorei Co. Ltd. saw their holdings diluted below certain notifiable thresholds. The issuance of shares to Hofseth International AS and Bomi Framroze Holding AS is pending approval at an extraordinary general meeting scheduled for July 30, 2026, though sufficient voting undertakings have been secured.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard